Dandiss Tech Co.,Ltd

Dandiss technology CO.,LTD is a fast-growing biopharmaceutical company that engages in the research, development and manufacturing of Active Pharmaceutical Ingredients and Intermediates with primary focus on the high-end API market and late-stage drug candidates. The Company has achieved revenue growth rate of over 100% annually since its establishment in 2001. It has been rewarded research grants by the Ministry of Science and Technology for innovative breakthroughs in a number of patented pharmaceutical intermediates.

Headquartered in the Center for New Medicine Discovery and Research in Hangzhou , BrightGene is aggressively committed to the commercialization of the following leading products in its rapidly expanding pipeline:

Entecavir and intermediates
Posaconazole intermediates
Fondaparinux sodium intermediate
Lapatinib intermediates
Pemetrexed disodium and intermediates
Aliskiren intermediates
In addition, our commitment extends to delivering excellent products and services for clients around the globe and partnering with companies and institutions whose strength will augment our own.
API and API's intermediate
Fondaparinux sodium
Aliskiren hemifumarate
Alvimopan
Entecavir monohydrate
Argatroban
Caspofungin
Posaconazole
Pemetrexed disodium
Telaprevir
Boceprevir
Latamoxef sodium
Sitagliptin
Ticagrelor
Bortezomib
Aprepitant
Fosaprepitant
Conjugated Estrogens
Sulfadoxine
Ebastine
Cilnidipine
Spironolactone

Standard material
standard of plant extracts
standard of drug
standard of drug's impurity

Plant extracts
Nobiletin
Andrographolide
Kaempferol
Ursolic acid
Oleanolic acid
Fisetin
Rutin trihydrate
Hyperoside
Myricetin